{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T03:28:42Z","timestamp":1795058922729,"version":"4.10.2"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["Inv-062781"],"award-info":[{"award-number":["Inv-062781"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Evidence is needed for single-dose human papillomavirus (HPV) vaccine efficacy (VE) durability to support vaccination guidelines. In this randomized crossover trial (NCT03675256), healthy young women aged 15-20 years, recruited through community-based screening in Kenya, were randomly allocated to immediate nonavalent or bivalent HPV vaccination and delayed control at month 30\/36 (age 17-23 years), or immediate control and delayed nonavalent HPV\u00a0vaccination. Cervical swabs collected every six months were tested for HPV DNA to determine incident persistent HPV infection. The primary outcome was VE at 54 months, estimated among participants who were HPV naive at enrollment vaccination using Cox proportional hazards models with time-varying covariates for HPV vaccine status and time; negative coefficients for time since vaccination indicate durability. For incident persistent HPV 16\/18 infections, 104 were detected: 93 pre-crossover and 11 post-crossover; HPV 16\/18 VE was 99.3% (95% CI: 96.2,99.9%). For incident persistent HPV 16\/18\/31\/33\/45\/52\/58, 117 infections occurred: 103 pre-crossover and 14 post-crossover; HPV 16\/18\/31\/33\/45\/52\/58 VE was 98.9% (95% CI: 94.9,99.8%). Coefficients for time since vaccination were \u22120.0014 (95% CI: \u22120.0027,\u22120.0002) for HPV 16\/18 and \u22120.0016 (95% CI: \u22120.0028,\u22120.0004) for HPV 16\/18\/31\/33\/45\/52\/58. Single-dose HPV vaccination is highly efficacious (\u2009&gt;\u200998%) and durable over 54 months in young women.<\/jats:p>","DOI":"10.1038\/s41467-026-72654-8","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T03:34:28Z","timestamp":1778470468000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and durability of immediate versus delayed single-dose HPV vaccination for persistent infection among young women in Kenya: a randomized, blinded, cross-over clinical trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1793-6003","authenticated-orcid":false,"given":"Ruanne V.","family":"Barnabas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4286-2111","authenticated-orcid":false,"given":"Elizabeth R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Bukusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Njoroge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6713-6127","authenticated-orcid":false,"given":"Denise A.","family":"Galloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imeldah N.","family":"Wakhungu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene","family":"Biwott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syovata","family":"Kimanthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8886-055X","authenticated-orcid":false,"given":"Kate B.","family":"Heller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meighan","family":"Krows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena A.","family":"Rechkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Cherne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Scott","family":"McClelland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly R.","family":"Mugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maricianah A.","family":"Onono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"72654_CR1","doi-asserted-by":"crossref","unstructured":"Wu, J. et al. Global burden of cervical cancer: current estimates, temporal trend and future projections based on the GLOBOCAN 2022. JNCC 5, 322\u2013329 (2025).","DOI":"10.1016\/j.jncc.2024.11.006"},{"key":"72654_CR2","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1016\/S2214-109X(22)00501-0","volume":"11","author":"D Singh","year":"2023","unstructured":"Singh, D. et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob. Health 11, e197\u2013e206 (2023).","journal-title":"Lancet Glob. Health"},{"key":"72654_CR3","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.3332\/ecancer.2022.1442","volume":"16","author":"V Mwenda","year":"2022","unstructured":"Mwenda, V. et al. Cervical cancer programme, Kenya, 2011-2020: lessons to guide elimination as a public health problem. Ecancermedicalscience 16, 1442 (2022).","journal-title":"Ecancermedicalscience"},{"key":"72654_CR4","doi-asserted-by":"publisher","first-page":"e0250113","DOI":"10.1371\/journal.pone.0250113","volume":"16","author":"C Ngcamphalala","year":"2021","unstructured":"Ngcamphalala, C., Ostensson, E. & Ginindza, T. G. The economic burden of cervical cancer in Eswatini: societal perspective. PLoS ONE 16, e0250113 (2021).","journal-title":"PLoS ONE"},{"key":"72654_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ygyno.2006.12.010","volume":"105","author":"S Arrossi","year":"2007","unstructured":"Arrossi, S. et al. The socio-economic impact of cervical cancer on patients and their families in Argentina, and its influence on radiotherapy compliance. Results from a cross-sectional study. Gynecol. Oncol. 105, 335\u2013340 (2007).","journal-title":"Gynecol. Oncol."},{"key":"72654_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2024.101355","volume":"52","author":"V Mwenda","year":"2024","unstructured":"Mwenda, V. et al. Factors associated with late diagnosis of cervical cancer at two national referral hospitals, Kenya 2017: a case control study. Gynecol. Oncol. Rep. 52, 101355 (2024).","journal-title":"Gynecol. Oncol. Rep."},{"key":"72654_CR7","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ygyno.2017.04.004","volume":"146","author":"DM Harper","year":"2017","unstructured":"Harper, D. M. & DeMars, L. R. HPV vaccines - A review of the first decade. Gynecol. Oncol. 146, 196\u2013204 (2017).","journal-title":"Gynecol. Oncol."},{"key":"72654_CR8","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1016\/S0140-6736(17)31821-4","volume":"390","author":"WK Huh","year":"2017","unstructured":"Huh, W. K. et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet 390, 2143\u20132159 (2017).","journal-title":"Lancet"},{"key":"72654_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bpobgyn.2017.08.015","volume":"47","author":"S de Sanjose","year":"2018","unstructured":"de Sanjose, S., Brotons, M. & Pavon, M. A. The natural history of human papillomavirus infection. Best. Pr. Res Clin. Obstet. Gynaecol. 47, 2\u201313 (2018).","journal-title":"Best. Pr. Res Clin. Obstet. Gynaecol."},{"key":"72654_CR10","unstructured":"World Health Organization. Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem. World Health Organization (2020)."},{"key":"72654_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2020.106399","volume":"144","author":"L Bruni","year":"2021","unstructured":"Bruni, L. et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019. Prev. Med. 144, 106399 (2021).","journal-title":"Prev. Med."},{"key":"72654_CR12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","volume":"394","author":"M Drolet","year":"2019","unstructured":"Drolet, M., Benard, E., Perez, N., Brisson, M. & H. P. V. Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet 394, 497\u2013509 (2019).","journal-title":"Lancet"},{"key":"72654_CR13","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2468-2667(21)00046-3","volume":"6","author":"M Bonjour","year":"2021","unstructured":"Bonjour, M. et al. Global estimates of expected and preventable cervical cancers among girls born between 2005 and 2014: a birth cohort analysis. Lancet Public Health 6, e510\u2013e521 (2021).","journal-title":"Lancet Public Health"},{"key":"72654_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1172\/JCI85446","volume":"126","author":"DR Lowy","year":"2016","unstructured":"Lowy, D. R. HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions. J. Clin. Invest. 126, 5\u201311 (2016).","journal-title":"J. Clin. Invest."},{"key":"72654_CR15","doi-asserted-by":"publisher","first-page":"e1485","DOI":"10.1016\/S2214-109X(22)00306-0","volume":"10","author":"K Baisley","year":"2022","unstructured":"Baisley, K. et al. Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial. Lancet Glob. Health 10, e1485\u2013e1493 (2022).","journal-title":"Lancet Glob. Health"},{"key":"72654_CR16","doi-asserted-by":"publisher","first-page":"EVIDoa2100056","DOI":"10.1056\/EVIDoa2100056","volume":"1","author":"RV Barnabas","year":"2022","unstructured":"Barnabas, R. V. et al. Efficacy of single-dose HPV vaccination among young African women. NEJM Evid. 1, EVIDoa2100056 (2022).","journal-title":"NEJM Evid."},{"key":"72654_CR17","doi-asserted-by":"crossref","unstructured":"Basu, P. et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16\/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncol. 22, 1518\u20131529 (2021).","DOI":"10.1016\/S1470-2045(21)00453-8"},{"key":"72654_CR18","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1016\/j.vaccine.2017.12.078","volume":"36","author":"AR Kreimer","year":"2018","unstructured":"Kreimer, A. R. et al. Evidence for single-dose protection by the bivalent HPV vaccine-review of the Costa Rica HPV vaccine trial and future research studies. Vaccine 36, 4774\u20134782 (2018).","journal-title":"Vaccine"},{"key":"72654_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf168","volume":"12","author":"A Cherif","year":"2025","unstructured":"Cherif, A. et al. Estimating the age of disease-causal HPV infection based on the natural history of CIN2+ among females in Canada. Open Forum Infect. Dis. 12, ofaf168 (2025).","journal-title":"Open Forum Infect. Dis."},{"key":"72654_CR20","unstructured":"Henschke, N. et al. Efficacy, Effectiveness and Immunogenicity of One Dose of HPV Vaccine Compared with No Vaccination, Two Doses, or Three Doses (Cochrane Response, 2022)."},{"key":"72654_CR21","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.1016\/j.vaccine.2022.06.065","volume":"40","author":"LE Markowitz","year":"2022","unstructured":"Markowitz, L. E. et al. Human papillomavirus vaccine effectiveness by number of doses: updated systematic review of data from national immunization programs. Vaccine 40, 5413\u20135432 (2022).","journal-title":"Vaccine"},{"key":"72654_CR22","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.vaccine.2019.12.017","volume":"38","author":"HS Whitworth","year":"2020","unstructured":"Whitworth, H. S. et al. Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: a systematic review of evidence from clinical trials. Vaccine 38, 1302\u20131314 (2020).","journal-title":"Vaccine"},{"key":"72654_CR23","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1038\/s41591-023-02658-0","volume":"29","author":"RV Barnabas","year":"2023","unstructured":"Barnabas, R. V. et al. Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results. Nat. Med 29, 3224\u20133232 (2023).","journal-title":"Nat. Med"},{"key":"72654_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/jncimonographs\/lgae032","volume":"2024","author":"C Porras","year":"2024","unstructured":"Porras, C. et al. HPV16\/18 antibodies 16-years after single dose of bivalent HPV vaccination: Costa Rica HPV vaccine trial. J. Natl. Cancer Inst. Monogr. 2024, 329\u2013336 (2024).","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"72654_CR25","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","volume":"394","author":"M Drolet","year":"2019","unstructured":"Drolet, M., Benard, E., Perez, N., Brisson, M. & Group, H. P. V. V. I. S. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet 394, 497\u2013509 (2019).","journal-title":"Lancet"},{"key":"72654_CR26","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0140-6736(24)01097-3","volume":"404","author":"F Wei","year":"2024","unstructured":"Wei, F., Georges, D., Man, I., Baussano, I. & Clifford, G. M. Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature. Lancet 404, 435\u2013444 (2024).","journal-title":"Lancet"},{"key":"72654_CR27","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.7326\/M20-8149","volume":"174","author":"D Follmann","year":"2021","unstructured":"Follmann, D. et al. A deferred-vaccination design to assess durability of COVID-19 vaccine effect after the placebo group is vaccinated. Ann. Intern Med 174, 1118\u20131125 (2021).","journal-title":"Ann. Intern Med"},{"key":"72654_CR28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1470-2045(18)30763-0","volume":"20","author":"NJ Polman","year":"2019","unstructured":"Polman, N. J. et al. Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. Lancet Oncol. 20, 229\u2013238 (2019).","journal-title":"Lancet Oncol."},{"key":"72654_CR29","doi-asserted-by":"crossref","unstructured":"Shadab, R. et al. Key ethical considerations to guide the adjudication of a single-dose HPV vaccine schedule. Hum. Vaccin. Immunother 18, 1\u20136 (2021).","DOI":"10.1080\/21645515.2021.1917231"},{"key":"72654_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05608-8","volume":"22","author":"RV Barnabas","year":"2021","unstructured":"Barnabas, R. V. et al. Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial. Trials 22, 661 (2021).","journal-title":"Trials"},{"key":"72654_CR31","doi-asserted-by":"publisher","first-page":"276","DOI":"10.5858\/arpa.2015-0117-OA","volume":"140","author":"S Jung","year":"2016","unstructured":"Jung, S., Lee, B., Lee, K. N., Kim, Y. & Oh, E. J. Clinical validation of anyplex II HPV HR detection test for cervical cancer screening in Korea. Arch. Pathol. Lab. Med. 140, 276\u2013280 (2016).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"72654_CR32","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1128\/JCM.03195-13","volume":"52","author":"AT Hesselink","year":"2014","unstructured":"Hesselink, A. T. et al. Clinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region. J. Clin. Microbiol. 52, 890\u2013896 (2014).","journal-title":"J. Clin. Microbiol."},{"key":"72654_CR33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jcv.2018.01.016","volume":"101","author":"C Eklund","year":"2018","unstructured":"Eklund, C., Forslund, O., Wallin, K. L. & Dillner, J. Continuing global improvement in human papillomavirus DNA genotyping services: the 2013 and 2014 HPV LabNet international proficiency studies. J. Clin. Virol. 101, 74\u201385 (2018).","journal-title":"J. Clin. Virol."},{"key":"72654_CR34","doi-asserted-by":"crossref","unstructured":"Heller, K. B. et al. High agreement of Seegene AnyplexTM HPV 28 and AllplexTM HPV 28 for high-risk vaccine-type HPV detection in the KEN SHE study. J. Virol. Methods (2026). In press.","DOI":"10.2139\/ssrn.6128112"},{"key":"72654_CR35","unstructured":"DAIDS. DAIDS Adverse Event Grading Tables. Vol. 2021 (2018)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72654-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72654-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72654-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T06:29:38Z","timestamp":1784183378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72654-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["72654"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-72654-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.V.B. reports grant support from the Gates Foundation and the National Institutes of Health, as well as serving on a Gilead Sciences DMC, for which she received an honorarium, outside the submitted work. D.A.G. reports honoraria received from Merck for advisory board membership, outside the submitted work. R.S.M. reports receiving donated STI testing supplies and research funding from Hologic Corporation, outside of the submitted work. All other coauthors have nothing to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6289"}}